There are 2185 resources available
1146MO - Interim analysis of CABONEN: A multicenter phase II trial investigating cabozantinib in patients with advanced, low proliferative NEN G3
Presenter: Alexander Otto Koenig
Session: Mini oral session: NETs and endocrine tumours
Resources:
Abstract
990O - Final results from phase I, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors
Presenter: Ruth Perets
Session: Proffered paper session: Investigational immunotherapy
Resources:
Abstract
LBA62 - Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): Results from the randomized phase II trial PANDAS/PRODIGE 44
Presenter: Aurélien Lambert
Session: Proffered paper session 1: GI tumours, upper digestive
Resources:
Abstract
LBA20 - First-line carboplatin-cyclophosphamide (CC) versus paclitaxel (P) with or without atezolizumab (atezo) for metastatic triple negative breast cancer (mTNBC): Results from a multicenter, randomized phase IIb trial: The Triple-B study (BOOG 2013-01)
Presenter: Marleen Kok
Session: Proffered paper session: Breast cancer, metastatic
Resources:
Abstract
991O - First-in-human (FIH) phase I data of HST-1011, an oral CBL-B inhibitor, in patients with advanced solid tumors
Presenter: Rachel Sanborn
Session: Proffered paper session: Investigational immunotherapy
Resources:
Abstract
606O - Initial results from a first-in-human study of the B7-H4-directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors
Presenter: Funda Meric-Bernstam
Session: Proffered paper session 1: Developmental therapeutics
Resources:
Abstract
1723MO - Axitinib plus avelumab in patients with unresectable/metastatic gastrointestinal stromal tumor (GIST) after failure of standard therapy: Single-arm phase II study (AXAGIST)
Presenter: Piotr Rutkowski
Session: Mini oral session: Sarcoma
Resources:
Abstract
1147MO - Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): An AIO phase II multicenter single-arm study
Presenter: Sebastian Krug
Session: Mini oral session: NETs and endocrine tumours
Resources:
Abstract
LBA40 - Primary results from the phase III ALTN-AK105-III-02 study: Anlotinib plus penpulimab versus sorafenib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
Presenter: Jian Zhou
Session: Proffered paper session 1: GI tumours, upper digestive
Resources:
Abstract
607O - Interim results of a phase I study of SGN-PDL1V (PF-08046054) in patients with PDL1-expressing solid tumors
Presenter: Marc Oliva Bernal
Session: Proffered paper session 1: Developmental therapeutics
Resources:
Abstract